New Data for MS drug Tysabri released at AAN annual meeting
Posted: Thu May 01, 2014 5:35 am
- New Tysabri® analysis shows improved walking speed in significant number of MS patients.
- Additional data show escalation to Tysabri following relapse improves clinical outcomes compared to remaining on or switching between first-line Interferon Beta and Glatiramer Acetate.............. Read More - http://www.ms-uk.org/tysabri
- Additional data show escalation to Tysabri following relapse improves clinical outcomes compared to remaining on or switching between first-line Interferon Beta and Glatiramer Acetate.............. Read More - http://www.ms-uk.org/tysabri